Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer

Osugi, Jun; Muto, Satoshi; Matsumura, Yuki; Higuchi, Mitsunori; Suzuki, Hiroyuki; Gotoh, Mitsukazu

doi:10.4103/0973-1482.176168

Cited by 42 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The flow diagram of this study is presented in Fig 1 . A total of 10 publications with 5817 patients were included in the meta-analysis [ 8 – 17 ]. One publication included two different cohorts (operative, inoperative) and reported their HRs separately, so we treated it as two studies [ 13 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis

Jin

Zhou

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

ObjectiveTo perform a meta-analysis of prospective and retrospective studies exploring the association of the modified Glasgow prognostic score (mGPS) with overall survival (OS) in patients with lung cancer.MethodsRelevant studies were identified by searching the Cochrane Library, Web of Science, Embase and PubMed until April 16, 2017. We combined hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the correlation between mGPS and OS in patients with lung cancer.ResultsEleven studies involving 5817 participants from several countries were included in the meta-analysis. In a pooled analysis of all studies, elevated mGPS predicted poorer OS (HR = 1.77; 95% CI: 1.35–2.31; P<0.05). Subgroup analyses stratified by mGPS showed that mGPS of 1 or 2 and mGPS≥1 were predictive of poorer OS and that the HR for mGPS of 2 (HR = 5.82; 95% CI: 1.85–18.22; P = 0.003) was significantly greater than that for mGPS of 1 (HR = 1.74; 95% CI: 1.24–2.45; P = 0.001) and mGPS≥1 (HR = 1.42; 95% CI: 1.14–1.76; P = 0.002). Among patients undergoing surgery, elevated mGPS had a non-significant correlation with reduced OS (HR = 2.48; 95% CI: 0.90–6.85; P = 0.079), whereas the correlation was significant for patients receiving chemotherapy or other palliative treatment (HR = 1.74; 95% CI: 1.31–2.30; P<0.05).ConclusionsOur findings indicate that mGPS may have prognostic value in lung cancer, as we detected a significant association between elevated mGPS and poorer OS. The association between mGPS and poorer OS was non-significant among patients undergoing surgery, which may be attributable to lower tumor load. However, further studies are warranted to draw firm conclusions.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Although accumulated evidence has demonstrated the clinical utility of mGPS in patients with different stages of lung cancer [ 8 – 17 ], data remain scarce and inconsistent. Therefore, we collected available publications and conducted a meta-analysis to explore the prognostic value of mGPS for OS in lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis

Jin

Zhou

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Among these markers, the NLR, PLR, and MLR—each of which can be easily calculated—have shown great potential. Several research studies[36,37] showed that PLR and NLR can help in the diagnosis of malignant tumors and in predicting prognosis. However, few studies have used the PLR and MLR as predictors of peritoneal metastasis.…”

Section: Discussionmentioning

confidence: 99%

Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer

Chen

Mao

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

The aims of the present study were to evaluate the predictive value of the platelet-to-lymphocyte ratio for peritoneal metastasis in patients with gastric cancer and to construct an available preoperative prediction system for peritoneal metastasis. A total of 1080 patients with gastric cancer were enrolled in our study. The preoperative platelet-to-lymphocyte ratio and other serum markers and objective clinical tumor characteristics were evaluated by receiver operating characteristic curves. A logistic analysis was performed to determine the independent predictive indicators of peritoneal metastasis. A prediction system that included the independent predictive indicators was constructed and evaluated by receiver operating characteristic curves. Based on the receiver operating characteristic curves, the ideal platelet-to-lymphocyte ratio cutoff value to predict peritoneal metastasis was 131.00. The logistic analysis showed that the platelet-to-lymphocyte ratio was an independent indicator to predict peritoneal metastasis. The area under the receiver operating characteristic curve was 0.599. When integrating all independent indicators (i.e., platelet-to-lymphocyte ratio, invasion depth, lymphatic invasion, pathological type), the prediction system more reliably predicted peritoneal metastasis with a higher area under the receiver operating characteristic curve (0.769). The preoperative platelet-to-lymphocyte ratio was an indicator that could be used to predict peritoneal metastasis. Our prediction system could be a reliable instrument to discriminate between patients with gastric cancer with and those without peritoneal metastasis.

show abstract

“…GPS was derived from the acute-phase proteins C-reactive protein and albumin, which were more sensitive and reliable markers that reflect the systemic inflammatory response in cancer patients. Until now, GPS has been shown to be a favorable predictor of survival in patients with various cancers [30,31,32,33]. Recently, more researchers are focusing on investigating the modified GPS, named mGPS, which also is a combination of C-reactive protein and albumin [34].…”

Section: Discussionmentioning

confidence: 99%

A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma

Chen

Liu

et al. 2016

IJMS

View full text Add to dashboard Cite

Recent studies have indicated that inflammation-based prognostic scores, such as the Glasgow Prognostic Score (GPS), modified GPS (mGPS) and C-reactive protein/Albumin (CRP/Alb) ratio, platelet–lymphocyte ratio (PLR), and neutrophil–lymphocyte ratio (NLR), have been reported to have prognostic value in patients with many types of cancer, including nasopharyngeal carcinoma (NPC). In this study, we proposed a novel inflammation-based stage, named I stage, for patients with NPC. A retrospective study of 409 newly-diagnosed cases of NPC was conducted. The prognostic factors (GPS, mGPS, CRP/Alb ratios, PLR, and NLR) were evaluated using univariate and multivariate analyses. Then, according to the results of the multivariate analyses, we proposed a I stage combination of independent risk factors (CRP/Alb ratio and PLR). The I stage was calculated as follows: patients with high levels of CRP/Alb ratio (>0.03) and PLR (>146.2) were defined as I2; patients with one or no abnormal values were defined as I1 or I0, respectively. The relationships between the I stage and clinicopathological variables and overall survival (OS) were evaluated. In addition, the discriminatory ability of the I stage with other inflammation-based prognostic scores was assessed using the AUCs (areas under the curves) analyzed by receiver operating characteristics (ROC) curves. The p value of <0.05 was considered to be significant. A total of 409 patients with NPC were enrolled in this study. Multivariate analyses revealed that only the CRP/Alb ratio (Hazard ratio (HR) = 2.093; 95% Confidence interval (CI): 1.222–3.587; p = 0.007) and PLR (HR: 2.003; 95% CI: 1.177–3.410; p = 0.010) were independent prognostic factors in patients with NPC. The five-year overall survival rates for patients with I0, I1, and I2 were 92.1% ± 2.9%, 83.3% ± 2.6%, and 63.1% ± 4.6%, respectively (p < 0.001). The I stage had a higher area under the curve value (0.670) compared with other systemic inflammation-based prognostic scores (p < 0.001). The I stage is a novel and useful predictive factor for OS in patients with NPC.

show abstract

Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer

Cited by 42 publications

References 0 publications

Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis

Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis

Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer

A Novel Inflammation-Based Stage (I Stage) Predicts Overall Survival of Patients with Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About